Usio Partners with Voyager Digital to Enable Merchants and ISVs to Accept Cryptocurrency as a Form of Payment

New partnership illustrates Usio’s ongoing innovation; Will enable merchants to accept various widely-used cryptocurrencies as a form of payment with Voyager’s state-of-the-art, secure platform

SAN ANTONIO, Aug. 04, 2021 (GLOBE NEWSWIRE) — Usio, Inc. (Nasdaq: USIO), a FinTech and integrated electronic payment solutions provider, announced today that it has partnered with Voyager Digital, the fast-growing cryptocurrency app and platform, to enable its merchants to accept many prominent cryptocurrencies as payment.

Louis Hoch, President and Chief Executive Officer of Usio, said, “Since its inception, Usio has been an innovator in the FinTech industry. The introduction of new technology that enables our merchants to accept various types of cryptocurrencies as a form of tender for all of our payment acceptance solutions further illustrates our commitment to forward-thinking thought leadership in the industry. Use of cryptocurrency is on the rise. Providing our merchants with the ability to accept crypto safely and securely, just like we provide with traditional electronic payment options, will enable the merchants and ISV’s we serve to meet the increasingly diverse payment needs of their customers, which we anticipate will increase customer participation, retention and revenue. The development of this new technology further reinforces our commitment to cryptocurrency markets, which already includes supporting the electronic payment and disbursement needs of crypto exchanges and related organizations.”

Stephen Ehrlich, CEO and Co-Founder of Voyager said, “We are pleased to build on our strong, long-term relationship with Usio by partnering on this exciting, new initiative to facilitate cryptocurrency payments globally at the merchant and ISV-level. The combination of Usio’s innovative, client-facing technology and Voyager’s state-of-the-art, scalable and secure payment offering, via our recent Coinify acquisition, is coming together just as the adoption of cryptocurrency as a form of payment is experiencing exponential growth. This new program will provide both merchants and ISVs an efficient, cost-effective, and seamless tool that responds to the evolution in payment trends.”

Usio’s unique new product will enable merchants to accept cryptocurrency as payment in-person, online, via electronic invoice or text-to-pay, among others, and can be transacted using the Voyager app. Usio will support as many as sixty cryptocurrencies across the globe, making it simple, convenient, and safe. This is a new way for Usio merchants to allow customers to checkout with cryptocurrency for online purchases, donations, tax payments and more.   The introduction of a crypto option reinforces our commitment to offering Usio merchants more convenient options for their customers to pay. Customers can check out safely and easily, quickly converting cryptocurrency holdings to US dollars at checkout, with clear conversion rates and no additional fees–all in real time with no exchange risk in price fluctuation that some non-stable crypto currencies experience.

Usio expects this service to be available in late 2021.


About Usio, Inc.

Usio, Inc. (Nasdaq: USIO), a leading FinTech integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, crypto exchanges and card issuers. The Company operates credit, debit/prepaid, and ACH payment processing platforms to deliver convenient, world-class payment solutions and services to their clients. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector. Usio is headquartered in San Antonio, Texas, and has offices in Austin, Texas and Franklin, Tennessee, just outside of Nashville.  
Websites: www.usio.comwww.singularpayments.comwww.payfacinabox.comwww.akimbocard.com and www.usiooutput.com.


About Voyager Digital Ltd.

Voyager Digital Ltd. (CSE: VYGR; OTCQX: VYGVF; FRA: UCD2) is the fast-growing, publicly traded cryptocurrency platform founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to invest and trade in over 60 different crypto assets, with zero commissions, using its easy-to-use mobile application, and earn rewards of up to 12 percent APY on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approved or disapproved of the contents of this press release.


FORWARD-LOOKING STATEMENTS DISCLAIMER


Except for the historical information contained herein, the matters discussed in this release include forward-looking statements which are covered by safe harbors. Those statements include, but may not be limited to, all statements regarding management’s intent, belief and expectations, such as statements concerning our future and our operating and growth strategy. These forward-looking statements are identified by the use of words such as “believe,” “intend,” “look forward,” “anticipate,” “schedule,” and “expect” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks related to an economic downturn as a result of the COVID-19 pandemic, the realization of opportunities from the IMS acquisition, the management of the Company’s growth, the loss of key resellers, the relationships with the Automated Clearinghouse network, bank sponsors, third-party card processing providers and merchants, the security of our software, hardware and information, the volatility of the stock price, the need to obtain additional financing, risks associated with new tax legislation, and compliance with complex federal, state and local laws and regulations, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the fiscal year ended December 31, 2020. One or more of these factors have affected, and in the future, could affect the Company’s businesses and financial results in the future and could cause actual results to differ materially from plans and projections. The Company believes that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to management. The Company assumes no obligation to update any forward-looking statements, except as required by law.

Contact:

Joe Hassett, Investor Relations
[email protected]
484-686-6600

Michael Legg
Chief Communications Officer, Voyager Digital
(212) 547-8807
[email protected]

Voyager Public Relations Team 
[email protected]



Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex’s Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year.

“This is an exciting time for Vertex, as we continue to expand access to our cystic fibrosis portfolio around the world and prepare to bring forward new therapies with the potential to transform the treatment of multiple serious diseases,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Stuart built out our world-class commercial teams in both the U.S. and International and led the effort to secure the reimbursement of our medicines around the world. He also has played a key role evolving our operating model to ready us for continued expansion into new diseases and geographic areas. In his new role, Stuart will ensure that we are best positioned to maximize the potential of our innovative therapies, secure access for patients and drive continued growth for Vertex.”

As Vertex’s COO, Mr. Arbuckle oversees Vertex’s global Commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, market research, as well as Commercial Manufacturing and Supply Chain, and other activities that support the approved use of Vertex’s marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources and Corporate Communications functions.

Mr. Arbuckle has more than 30 years of experience leading global sales and marketing efforts at biopharmaceutical companies, including at Amgen and GlaxoSmithKline plc. Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen’s board of directors, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.

Mr. Arbuckle earned a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Vertex Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second, paragraph of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, risks listed under the heading “Risk Factors” in Vertex’s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated

Investors:

Michael Partridge, +1 617-341-6108

or

Brenda Eustace, +1 617-341-6187

or

Manisha Pai, +1 617-429-6891

Media:

[email protected]

or

U.S.: +1 617-341-6992

or

Heather Nichols: +1 617-839-3607

or

International: +44 20 3204 5275

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Other Health Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo

Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference

NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President will participate in a panel titled Miss Con-GENE-iality – Updates in Gene Tx on Wednesday, August 11, 2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370



IMV Announces CEO Transition

IMV Announces CEO Transition

Frederic Ors to Step Down as CEO

CBO Andrew Hall Appointed Interim CEO

Board Initiating Search for Permanent Successor

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–
IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Frederic Ors has stepped down as Chief Executive Officer (CEO), effective immediately. The IMV Board has appointed Andrew Hall, the Company’s Chief Business Officer, as Interim CEO. The Company’s Board is commencing a comprehensive search process to identify a permanent CEO.

“On behalf of the Board and everyone at IMV, I want to thank Fred for his valuable contributions and years of service to IMV,” said Andy Sheldon, Chairman of the IMV Board. “During Fred’s tenure, IMV successfully established the Company’s proprietary technology (DPX) as a novel immune-oncology platform. He led the company to demonstrate the value of this approach through the successful completion of clinical trials with the platform’s first development product, maveropepimut-S, proving clinical benefit for patients with both solid and liquid tumors. His vision, tenacity and leadership have been critical for building IMV’s story, and we wish him all the best in his future endeavors.”

Mr. Sheldon continued, “As IMV advances its proprietary DPX programs and platform to benefit cancer patients and create value for shareholders, the Board determined that now is the right time to transition to new leadership. With this transition, we look forward to IMV continuing to demonstrate the clinical utility of maveropepimut-S as well as expanding its platform to create additional novel therapeutics with the potential to improve the lives of cancer patients with high unmet medical need. With multiple important trials initiated and results expected in the coming months and years, we believe we can establish IMV as a leader in oncology immunotherapy.”

Mr. Sheldon concluded, “We have great confidence in the executive management team that will be continuing to lead IMV. Andrew Hall’s (formerly Celgene) strong operational expertise as interim CEO will position the company for positive change, the recent appointment of Dr. Jeremy Graff (formerly Lilly) as Chief Scientific Officer and the financial stewardship of Pierre Labbe as Chief Financial Officer position the company well. All three are seasoned executives with decades of leadership and operational experience. We appreciate that Andrew has agreed to step into the role of Interim CEO and are confident that this will be a seamless transition as we continue to advance and expand the IMV footprint in oncology.”

About Maveropepimut-S (DPX-Survivac)

Maveropepimut-S (or MVP-S, formerly named DPX-Survivac) is the lead candidate in IMV’s new class of immunotherapy that generates targeted and sustained cancer cell killing capabilities in vivo. Previous and ongoing clinical studies demonstrate that treatment with maveropepimut-S in association with CPA is well tolerated and has shown promising antitumor activity in a variety of tumor types.

Maveropepimut-S, consists of survivin-based peptides formulated in IMV’s proprietary delivery platform (DPX) which is designed to generate a sustained cytotoxic T cell response against cancer cells presenting survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by maveropepimut-S.

Maveropepimut-S has received Fast Track designation from the FDA as maintenance therapy in advanced ovarian cancer, as well as Orphan Drug designation status from the FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing hard-to-treat cancer and other unmet medical needs. IMV is pioneering a novel class of cancer immunotherapies based on the Company’s proprietary delivery platform (DPX). This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV’s lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy to be evaluated in subjects with bladder cancer. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

Cautionary Language Regarding Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Company’s ability to advance its development strategy, as well as the prospects, for its immunotherapies in oncology and elsewhere and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, the ability to access capital, the successful and, generally, the timely completion of clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.

O: (902) 492-1819 ext : 1042

M: (514) 617-9481

[email protected]

Irina Koffler, Managing Director, LifeSci Advisors

O: (646) 970-4681

M: (917) 734-7387

[email protected]

Media

Delphine Davan, Senior Director, Communications, IMV Inc.

(514) 968 1046

[email protected]

Madeline Joanis, Account Executive, LifeSci Communications

(603) 479 5267

[email protected]

KEYWORDS: United States North America Canada

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET

TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fiscal first quarter 2021 financial results on Tuesday, August 10, 2021, before the market opens.
Management will host a conference call on Tuesday, August 10, at 8:30 a.m. ET to review financial results and provide an update on corporate developments.

Following management’s formal remarks, there will be a question-and-answer session.
Participants are asked to pre-register for the call through the following link:
https://dpregister.com/sreg/10158721/eb2ec48868.

Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-844-854-4417 (domestic), or 1-412-317-5739 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the InspireMD call.

The conference call will also be available through a live webcast found here:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=a2t5MXpf.

Additionally, it will be broadcast live through the Company’s website via the following link:
https://www.inspiremd.com/en/investors/investor-relations/.

A webcast replay of the call will be available approximately one hour after the end of the call through November 10, 2021, at the above links. A telephonic replay of the call will be available through August 24, 2021 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10158721.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. For example, the Company is using forward-looking statements when it discusses the number of expected patients to be enrolled in the trial, that the initiation of the trial marks an important milestone for the potential approval of the CGuard EPS and towards advancing the treatment of CAD and stroke prevention, and that the initiation of the trial marks the beginning of the next step in the Company’s journey towards CGuard EPS being utilized in the U.S. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
[email protected]

CORE IR
[email protected]



Iteris to Present at Oppenheimer & Co Technology, Internet & Communications Conference on August 11, 2021

Iteris to Present at Oppenheimer & Co Technology, Internet & Communications Conference on August 11, 2021

SANTA ANA, Calif.–(BUSINESS WIRE)–Iteris, Inc. (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that it has been invited to present at the 24th Annual Oppenheimer & Co Technology, Internet & Communications Conference on Wednesday, August 11, 2021.

Iteris president and CEO Joe Bergera, and CFO Douglas Groves are scheduled to present at 3:45 p.m. ET (12:45 p.m. PT), and will be hosting virtual one-on-one meetings with investors throughout the day.

For additional information or to schedule a virtual meeting with Iteris management, please contact your Oppenheimer representative, or Iteris’ investor relations firm, MKR Investor Relations, at [email protected].

About Iteris, Inc.

Iteris is the global leader in smart mobility infrastructure management – the foundation for a new era of mobility. We apply cloud computing, artificial intelligence, advanced sensors, advisory services and managed services to achieve safe, efficient and sustainable mobility. Our end-to-end solutions monitor, visualize and optimize mobility infrastructure around the world to help ensure that roads are safe, travel is efficient, and communities thrive. Visit www.iteris.com for more information, and join the conversation on Twitter, LinkedIn and Facebook.

Iteris Contact

Douglas Groves

​​​​​​​Senior Vice President and Chief Financial Officer

Tel: (949) 270-9643

Email: [email protected]

Investor Relations

MKR Investor Relations, Inc.

Todd Kehrli

Tel: (213) 277-5550

Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Mobile/Wireless Internet Fleet Management Data Management Consumer Electronics General Automotive Public Transport Technology Automotive Construction & Property Urban Planning Transport

MEDIA:

Logo
Logo

Air Industries Group Reports 82.4% Second Quarter Revenue Growth

Air Industries Group Reports 82.4% Second Quarter Revenue Growth

Significantly Improved Financial Results for Both the Three and Six Months Ended June 30, 2021

BAY SHORE, N.Y.–(BUSINESS WIRE)–Air Industries Group (NYSE AMEX: AIRI):

Air Industries Group, an integrated manufacturer of precision equipment assemblies and components for leading aerospace and defense prime contractors today announced results for the three and six-month periods ended June 30, 2021.

Q2 Highlights

  • Receipt of $7.4 million order for ‘Thrust Struts’, a critical component of the Geared Turbofan (GTF) Jet Engine.

    • Our current fully funded backlog is $91.5 million.
  • Consolidated net sales increased by $7.0 million, or 82.4%, to $15.5 million compared with $8.5 million in Q2 2020.
  • Consolidated gross profit increased $2.0 million, or 333.3%, to $2.6 million compared with $600,000 in Q2 2020.

    • Gross profit as a percentage of sales was 16.8% compared with 7.1% in 2020.
  • Operating income increased by $1.7 million to $400,000 compared with an operating loss of $1.3 million in 2020.
  • Adjusted EBITDA increased $1.5 million to $1.4 million compared with an EBITDA loss of $100,000 in 2020.

Six-Month Highlights

  • Consolidated net sales increased by $7.3 million, or 33.3%, to $29.2 million compared with $21.9 million in 2020.
  • Consolidated gross profit increased $1.6 million, or 57.1%, to $4.4 million compared with $2.8 million in 2020.

    • Gross profit as a percentage of sales was 15.1% compared with 12.8% in 2020.
  • Operating income increased by $1.9 million to $500,000 compared with an operating loss of $1.4 million in 2020.
  • Adjusted EBITDA increased nearly $1.8 million, or nearly 225%, to $2.6 million compared with an EBITDA of $800,000 in 2020.

Reconciliation of Net Income to Adjusted EBITDA

       
  For the Six Months Ended June 30, 2021  
  Net Income

 $                   87,000

 
  Add-backs to EBITDA  
  Interest 

                    629,000

 
  Taxes

                               –

 
  Depreciation & Amortization

                 1,495,000

 
  EBITDA

                2,211,000

 
  Add-backs to Adjusted EBITDA  
  Bank Charges

                      26,000

 
  Stock Compensation

                    318,000

 
  Adjusted EBITDA

 $             2,555,000

 
       

CEO Commentary

Lou Melluzzo, CEO of Air Industries said, “The strong second quarter sales results delivered by our team was led by significant improvement at our Sterling manufacturing facility. The meaningful quarterly increases in gross profit and EBITDA were also driven by a more diverse product mix at CMS.

Also, during the quarter, as part of a long-term agreement for our largest commercial aviation product, we received a $7.4 million order for a critical component of the Geared Turbofan (GTF). Our current fully funded backlog is $91.5 million. In a manufacturing business such as ours, gross profit, operating profit, and EBITDA are highly correlated with revenue. The improvement in all these metrics illustrate the improved earnings leverage of the company.

Adding additional strength to our balance sheet, we are very pleased that we were able to reduce inventory by $2.0 million during the quarter – which grew as a result of Covid-19-related supply chain challenges. The improved financial results allow us to continue our robust capital investment program upgrading and enhancing our capabilities.”

Melluzzo concluded, “We are adding to the strong momentum and backlog of orders of the first six months with the previously announced three-year agreement in July to purchase $12 – $18 million of landing gear components for the F-35 Joint Strike Fighter Aircraft. We look forward to a strong second half of the year and anticipate that the improvements and enhancements we’ve initiated will continue to generate strong results.”

Investor Conference Call

The Company will host a conference call for investors on August 4, 2021 at 4:30 PM Eastern.

Conference Toll-Free Number: 1-888-207-0293 Passcode – 392 813

About Air Industries Group

Air Industries Group (AIRI) is an integrated manufacturer of precision equipment assemblies and components for leading aerospace and defense prime contractors. For more information visit www.airindustriesgroup.com.

Forward Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, earnings and Adjusted EBITDA, the ability to realize firm backlog and projected backlog, cost cutting measures, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of projects due to variability in size, scope and duration, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Adjusted EBITDA

The Company uses Adjusted EBITDA, a Non-GAAP financial measure as defined by the SEC, as a supplemental profitability measure because management finds it useful to understand and evaluate results, excluding the impact of non-cash depreciation and amortization charges, stock-based compensation expenses, and nonrecurring expenses and outlays, prior to consideration of the impact of other potential sources and uses of cash, such as working capital items. This calculation may differ in method of calculation from similarly titled measures used by other companies and may be different than the EBITDA calculation used by our lenders for purposes of determining compliance with our financial covenants. This Non-GAAP measure may have limitations when understanding performance as it excludes the financial impact of transactions such as interest expense necessary to conduct the Company’s business and therefore are not intended to be an alternative to financial measure prepared in accordance with GAAP. The Company has not quantitatively reconciled its forward-looking Adjusted EBITDA target to the most directly comparable GAAP measure because such items such as amortization of stock-based compensation and interest expense, which are specific items that impact these measures, have not yet occurred, are out of the Company’s control, or cannot be predicted. For example, quantification of stock-based compensation is not possible as it requires inputs such as future grants and stock prices which are not currently ascertainable.

Air Industries Group

Michael Recca – CFO

Investor Relations

631.328.7078

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Defense Contracts Steel Engineering Air Aerospace Transport Manufacturing

MEDIA:

Logo
Logo

Investors Title Company Announces Record Second Quarter 2021 Financial Results

Investors Title Company Announces Record Second Quarter 2021 Financial Results

CHAPEL HILL, N.C.–(BUSINESS WIRE)–
Investors Title Company today announced results for the second quarter ended June 30, 2021. The Company reported net income of $19.8 million, or $10.42 per diluted share, compared to $14.5 million, or $7.65 per diluted share, for the prior year period. The Company set all-time quarterly records for total revenues, net premiums written and net income.

Revenues for the quarter increased 37.6% to $85.0 million, compared with $61.7 million for the prior year quarter. Net premiums written increased 42.2% versus the prior year period, as lower average interest rates and ongoing economic recovery continued to drive strong levels of refinance activity and home sales. Higher transaction volumes drove a 72.8% increase in escrow and other title-related fees. Non-title services increased 21.9% due primarily to higher levels of property exchange transaction volumes and higher income levels from management services. Other investment income increased $957,000 due to earnings from partnership investments. Changes in the estimated fair value of equity security investments resulted in a benefit of $4.8 million, which was $3.1 million lower than the prior year quarter, as equity markets continued to rally following the dip from initial impacts of the COVID-19 pandemic in the prior year period. Other income increased $4.0 million due to a gain on the sale of property.

Operating expenses increased 36.2%, as commissions to agents increased commensurate with the increase in agent premium volume. Notwithstanding higher premium volumes, claims expense decreased 28.0% due to improved incurred claims experience and higher levels of favorable loss development related to prior policy years. Personnel costs were 29.9% higher than the prior year period due to staffing additions in support of strategic growth initiatives and volume increases. Higher premium volumes and ongoing technology initiatives drove the increase in other operating expenses.

Income before income taxes increased 41.1% to $25.3 million for the current quarter versus $17.9 million in the prior year period. Excluding the impact of changes in the estimated fair value of equity security investments, income before income taxes (non-GAAP) increased 105.6% to $20.5 million for the current quarter versus $10.0 million in the prior year period (see Appendix A for a reconciliation of this non-GAAP measure to the most directly comparable GAAP measure).

For the six months ended June 30, 2021, net income increased $26.1 million to $33.6 million, or $17.70 per diluted share, versus $7.5 million, or $3.95 per diluted share, for the prior year period. Revenues increased 71.3% to $157.0 million, versus $91.6 million in the prior year period. Operating expenses increased 39.1% to $114.4 million, mainly due to increases in agent commissions and personnel expenses. Aside from changes in the estimated fair value of equity security investments and claims expense, overall results for the year-to-date period have been shaped predominantly by the same factors that affected the second quarter.

Chairman J. Allen Fine added, “We are pleased to announce another quarter of record operating results for the Company. Overall, the trends that began last year following the onset of the pandemic continued to fuel strong demand for housing as well as high levels of refinance activity. The Company experienced revenue growth in all of its key markets and across all channels.

“The outlook for real estate activity for the remainder of the year continues to be generally positive. The pace of existing home sales has slowed in recent months as prices have continued to rise, however mortgage interest rates continue to hover near record low levels, and have offset some of the impact of higher prices. The economy overall is showing clear signs of recovery amid strong government stimulus measures, with more than half of the population receiving vaccinations, more establishments reopening, and unemployment levels continuing to fall. With these trends in mind, we believe 2021 will be another record year for the industry.”

Investors Title Company’s subsidiaries issue and underwrite title insurance policies. The Company also provides investment management services and services in connection with tax-deferred exchanges of like-kind property.

Cautionary Statements Regarding Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “plan,” expect,” “aim,” “believe,” “project,” “anticipate,” “intend,” “estimate,” “should,” “could,” “would,” and other expressions that indicate future events and trends. Such statements include, among others, any statements regarding the Company’s expected performance for this year, projections regarding U.S. recovery from the COVID-19 pandemic, future home price fluctuations, changes in home purchase or refinance demand, activity and the mix thereof, interest rate changes, expansion of the Company’s market presence, enhancing competitive strengths, positive development in housing affordability, wages, unemployment or overall economic conditions or statements regarding our actuarial assumptions and the application of recent historical claims experience to future periods. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from anticipated and historical results. Such risks and uncertainties include, without limitation: the severity and duration of the COVID-19 pandemic (including any of its variants) and its effects (and the effects of measures undertaken to combat it) on the economy and the Company’s business; the cyclical demand for title insurance due to changes in the residential and commercial real estate markets; the occurrence of fraud, defalcation or misconduct; variances between actual claims experience and underwriting and reserving assumptions, including the limited predictive power of historical claims experience; declines in the performance of the Company’s investments; government regulations; changes in the economy; changes resulting from President Biden’s administration and Congress; loss of agency relationships, or significant reductions in agent-originated business; difficulties managing growth, whether organic or through acquisitions and other considerations set forth under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission, and in subsequent filings.

Investors Title Company and Subsidiaries

Consolidated Statements of Operations

For the Three and Six Months Ended June 30, 2021 and 2020

(in thousands, except per share amounts)

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

June 30,

 

Six Months Ended

June 30,

 

 

2021

 

2020

 

2021

 

2020

Revenues:

 

 

 

 

 

 

 

 

Net premiums written

 

$

67,527

 

$

47,479

 

$

129,004

 

$

86,106

 

Escrow and other title-related fees

 

 

3,487

 

 

2,018

 

 

6,285

 

 

3,860

 

Non-title services

 

 

2,408

 

 

1,975

 

 

4,486

 

 

4,522

 

Interest and dividends

 

 

898

 

 

1,105

 

 

1,914

 

 

2,282

 

Other investment income

 

 

1,483

 

 

526

 

 

2,424

 

 

966

 

Net realized investment gains

 

 

182

 

 

553

 

 

503

 

 

141

 

Changes in the estimated fair value of equity security investments

 

 

4,829

 

 

7,972

 

 

8,068

 

 

(6,486

)

Other

 

 

4,147

 

 

120

 

 

4,355

 

 

258

 

Total Revenues

 

 

84,961

 

 

61,748

 

 

157,039

 

 

91,649

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

Commissions to agents

 

 

34,346

 

 

24,089

 

 

64,888

 

 

44,276

 

Provision for claims

 

 

1,436

 

 

1,994

 

 

3,027

 

 

2,900

 

Personnel expenses

 

 

15,914

 

 

12,248

 

 

32,067

 

 

24,057

 

Office and technology expenses

 

 

3,211

 

 

2,457

 

 

5,953

 

 

4,872

 

Other expenses

 

 

4,766

 

 

3,038

 

 

8,501

 

 

6,151

 

Total Operating Expenses

 

 

59,673

 

 

43,826

 

 

114,436

 

 

82,256

 

 

 

 

 

 

 

 

 

 

Income before Income Taxes

 

 

25,288

 

 

17,922

 

 

42,603

 

 

9,393

 

 

 

 

 

 

 

 

 

 

Provision for Income Taxes

 

 

5,506

 

 

3,427

 

 

8,998

 

 

1,909

 

 

 

 

 

 

 

 

 

 

Net Income

 

$

19,782

 

$

14,495

 

$

33,605

 

$

7,484

 

 

 

 

 

 

 

 

 

 

Basic Earnings per Common Share

 

$

10.44

 

$

7.66

 

$

17.74

 

$

3.96

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Basic

 

 

1,894

 

 

1,892

 

 

1,894

 

 

1,891

 

 

 

 

 

 

 

 

 

 

Diluted Earnings per Common Share

 

$

10.42

 

$

7.65

 

$

17.70

 

$

3.95

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Diluted

 

 

1,899

 

 

1,895

 

 

1,898

 

 

1,895

 

Investors Title Company and Subsidiaries

Consolidated Balance Sheets

As of June 30, 2021 and December 31, 2020

(in thousands)

(unaudited)

 

 

 

 

 

June 30,

2021

 

December 31,

2020

Assets

 

 

 

 

 

 

 

Cash and cash equivalents

$

31,583

 

$

13,723

 

 

 

 

Investments:

 

 

 

Fixed maturity securities, available-for-sale, at fair value

 

88,982

 

 

117,713

Equity securities, at fair value

 

69,915

 

 

64,919

Short-term investments

 

44,446

 

 

15,170

Other investments

 

15,031

 

 

15,493

Total investments

 

218,374

 

 

213,295

 

 

 

 

Premiums and fees receivable

 

21,388

 

 

19,427

Accrued interest and dividends

 

850

 

 

1,038

Prepaid expenses and other receivables

 

13,800

 

 

9,418

Property, net

 

15,010

 

 

11,160

Goodwill and other intangible assets, net

 

9,980

 

 

9,771

Operating lease right-of-use assets

 

3,383

 

 

3,533

Other assets

 

1,767

 

 

1,560

Current income taxes receivable

 

804

 

 

Total Assets

$

316,939

 

$

282,925

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

Liabilities:

 

 

 

Reserve for claims

$

35,303

 

$

33,584

Accounts payable and accrued liabilities

 

34,724

 

 

36,020

Operating lease liabilities

 

3,510

 

 

3,669

Current income taxes payable

 

 

 

638

Deferred income taxes, net

 

11,464

 

 

8,592

Total liabilities

 

85,001

 

 

82,503

 

 

 

 

Stockholders’ Equity:

 

 

 

Common stock no par value (10,000 authorized shares; 1,894 and 1,892 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively, excluding in each period 292 shares of common stock held by the Company’s subsidiary)

 

 

 

Retained earnings

 

228,133

 

 

196,096

Accumulated other comprehensive income

 

3,805

 

 

4,326

Total stockholders’ equity

 

231,938

 

 

200,422

Total Liabilities and Stockholders’ Equity

$

316,939

 

$

282,925

Investors Title Company and Subsidiaries

Net Premiums Written By Branch and Agency

For the Three and Six Months Ended June 30, 2021 and 2020

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended June 30,

Six Months Ended June 30,

 

2021

%

2020

%

2021

%

2020

%

Branch

$

17,048

25.2

$

12,973

27.3

$

34,408

26.7

$

22,868

26.6

 

 

 

 

 

 

 

 

 

Agency

 

50,479

74.8

 

34,506

72.7

 

94,596

73.3

 

63,238

73.4

 

 

 

 

 

 

 

 

 

Total

$

67,527

100.0

$

47,479

100.0

$

129,004

100.0

$

86,106

100.0

Investors Title Company and Subsidiaries

Appendix A

Non-GAAP Measures Reconciliation

For the Three and Six Months Ended June 30, 2021 and 2020

(in thousands)

(unaudited)

Management uses various financial and operational measurements, including financial information not prepared in accordance with generally accepted accounting principles (“GAAP”), to analyze Company performance. This includes adjusting revenues to remove the impact of changes in the estimated fair value of equity security investments, which are recognized in net income under GAAP. Management believes that these measures are useful to evaluate the Company’s internal operational performance from period to period because they eliminate the effects of external market fluctuations. The Company also believes users of the financial results would benefit from having access to such information, and that certain of the Company’s peers make available similar information. This information should not be used as a substitute for, or considered superior to, measures of financial performance prepared in accordance with GAAP, and may be different from similarly titled non-GAAP financial measures used by other companies.

The following tables reconcile non-GAAP financial measurements used by Company management to the comparable measurements using GAAP:

 

Three Months Ended

June 30,

 

Six Months Ended

June 30,

 

2021

 

2020

 

2021

 

2020

 

 

 

 

 

 

 

 

Revenues

 

 

 

 

 

 

 

Total revenues (GAAP)

$

84,961

 

 

$

61,748

 

 

$

157,039

 

 

$

91,649

(Subtract) Add: Changes in the estimated fair value of equity security investments

 

(4,829

)

 

 

(7,972

)

 

 

(8,068

)

 

 

6,486

Adjusted revenues (non-GAAP)

$

80,132

 

 

$

53,776

 

 

$

148,971

 

 

$

98,135

 

 

 

 

 

 

 

 

Income before Income Taxes

 

 

 

 

 

 

 

Income before income taxes (GAAP)

$

25,288

 

 

$

17,922

 

 

$

42,603

 

 

$

9,393

(Subtract) Add: Changes in the estimated fair value of equity security investments

 

(4,829

)

 

 

(7,972

)

 

 

(8,068

)

 

 

6,486

Adjusted income before income taxes (non-GAAP)

$

20,459

 

 

$

9,950

 

 

$

34,535

 

 

$

15,879

 

Elizabeth B. Lewter

Telephone: (919) 968-2200

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Logo
Logo

BrightSpire Capital, Inc. Announces Second Quarter 2021 Financial Results

BrightSpire Capital, Inc. Announces Second Quarter 2021 Financial Results

NEW YORK–(BUSINESS WIRE)–
BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced its financial results for the second quarter ended June 30, 2021 and certain updates. The Company reported second quarter 2021 GAAP net loss attributable to common stockholders of $(19.7) million, or $(0.15) per share, and Distributable Loss of $(27.1) million, or $(0.20) per share. Excluding realized losses on sales and fair value adjustments, Adjusted Distributable Earnings were $27.0 million, or $0.20 per share. The Company reported GAAP net book value of $11.75 per share and undepreciated book value of $12.66 per share as of June 30, 2021.

Michael J. Mazzei, Chief Executive Officer and President, commented, “The first half of 2021 has been highlighted by reinstating and increasing our quarterly dividend, internalizing the management of the Company and rebranding, placing a portfolio of development and non-accrual co-investments under contract, and executing on a new CRE CLO. We continue to simplify the business and remain focused on increasing portfolio exposure to senior mortgages.”

Mr. Mazzei continued, “The strength of our loan origination business and team resulted in the successful execution of our second managed $800 million CRE CLO and first as an internally managed REIT. The transaction improves our return on equity and the liquidity generated from the transaction will be invested in new senior loan originations. Since late 2020, we have closed or committed over $1.5 billion in senior loans.”

Mr. Mazzei continued, “Finally, I am pleased to announce that we have increased our quarterly dividend from $0.14 to $0.16 per share for the third quarter of 2021.”

Supplemental Financial Report

A Second Quarter 2021 Supplemental Financial Report is available on the Shareholders – Events and Presentations section of the Company’s website at www.brightspire.com. This information will be furnished to the SEC in a Current Report on Form 8-K.

We refer to “Distributable Earnings,” which is a non-GAAP financial measure, in this release. A reconciliation to net income/(loss) attributable to BrightSpire Capital, the most directly comparable GAAP measure, is included in our full detailed Second Quarter 2021 Supplemental Financial Report and is available on our website at www.brightspire.com.

Second Quarter 2021 Conference Call

The Company will conduct a conference call to discuss the financial results on August 4, 2021 at 7:00 a.m. PT / 10:00 a.m. ET. To participate in the event by telephone, please dial (877) 407-0784 ten minutes prior to the start time (to allow time for registration). International callers should dial (201) 689-8560. The call will also be broadcast live over the Internet and can be accessed on the Shareholders section of the Company’s website at www.brightspire.com. A webcast of the call will be available for 90 days on the Company’s website.

For those unable to participate during the live call, a replay will be available starting August 4, 2021 at 10:00 a.m. PT / 1:00 p.m. ET, through August 11, 2021, at 8:59 p.m. PT / 11:59 p.m. ET. To access the replay, dial (844) 512-2921 and use conference ID code 13721111. International callers should dial (412) 317-6671 and enter the same conference ID.

Dividend Announcement

On August 4, 2021, the Company’s Board of Directors declared a quarterly cash dividend of $0.16 per share to holders of Class A common stock for the third quarter of 2021, which will be paid on October 15, 2021, to common stockholders of record on September 30, 2021.

Previously, on May 5, 2021, the Company’s Board of Directors declared a quarterly cash dividend of $0.14 per share to holders of Class A common stock for the second quarter of 2021, which was paid on July 15, 2021, to common stockholders of record on June 30, 2021.

About BrightSpire Capital, Inc.

BrightSpire Capital, Inc. (NYSE: BRSP), formerly Colony Credit Real Estate, Inc. (NYSE: CLNC), is internally managed and one of the largest publicly traded commercial real estate (CRE) credit REITs, focused on originating, acquiring, financing and managing a diversified portfolio consisting primarily of CRE debt investments and net leased properties predominantly in the United States. CRE debt investments primarily consist of first mortgage loans, which we expect to be the primary investment strategy. BrightSpire Capital is organized as a Maryland corporation and taxed as a REIT for U.S. federal income tax purposes. For additional information regarding the Company and its management and business, please refer to www.brightspire.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and contingencies, many of which are beyond our control, and may cause actual results to differ significantly from those expressed in any forward-looking statement. Among others, the following uncertainties and other factors could cause actual results to differ from those set forth in the forward-looking statements: operating costs and business disruption may be greater than expected; uncertainties regarding the ongoing impact of the novel coronavirus (COVID-19) and its adverse impact on the real estate market, the economy and the Company’s investments (including, but not limited to, the Los Angeles mixed-use development loan, other hospitality loans, and Dublin development financings), financial condition and business operation; the Company’s operating results may differ materially from the information presented in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in the Company’s other filings with the Securities and Exchange Commission; the fair value of the Company’s investments may be subject to uncertainties; the Company’s use of leverage could hinder its ability to make distributions and may significantly impact its liquidity position; the ability to simplify the portfolio, realize substantial efficiencies as well as anticipated strategic and financial benefits, including, but not limited to expected cost savings through the internalization or expected returns on equity and/or yields on investments; the timing of and ability to generate additional liquidity and deploy available liquidity, including in senior mortgage loans; whether the Company will achieve its anticipated Distributable Earnings per share (as adjusted), or maintain or produce higher Distributable Earnings per share (as adjusted) in the near term or ever; the Company’s ability to maintain or grow the dividend at all in the future; defaults by borrowers in paying debt service on outstanding indebtedness, borrowers’ abilities to manage and stabilize properties; deterioration in the performance of the properties securing our investments (including depletion of interest and other reserves or payment-in-kind concessions in lieu of current interest payment obligations) that may cause deterioration in the performance of our investments and, potentially, principal losses to us; adverse impacts on the Company’s corporate revolver, including covenant compliance and borrowing base capacity; adverse impacts on the Company’s liquidity, including margin calls on master repurchase facilities; lease payment defaults or deferrals, demands for protective advances and capital expenditures; the ability of the Company to refinance certain mortgage debt on similar terms to those currently existing or at all; the ability to execute CRE CLO’s on a go forward basis, including at a reduced cost of capital; the conditions to the completion of the co-invest portfolio sale may not be satisfied, or the approvals required for the transaction may not be obtained on the terms expected, on the anticipated schedule, or at all; the timing or ability to payoff off the 5-investment preferred financing following the co-invest portfolio sale and net effect book value for such events (including the extent of purchase price adjustments); and the impact of legislative, regulatory and competitive changes, and the actions of government authorities and in particular those affecting the commercial real estate finance and mortgage industry or our business. The foregoing list of factors is not exhaustive. Additional information about these and other factors can be found in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in BrightSpire Capital’s other filings with the Securities and Exchange Commission. Moreover, each of the factors referenced above are likely to also be impacted directly or indirectly by the ongoing impact of COVID-19 and investors are cautioned to interpret substantially all of such statements and risks as being heightened as a result of the ongoing impact of the COVID-19.

We caution investors not to unduly rely on any forward-looking statements. The forward-looking statements speak only as of the date of this press release. BrightSpire Capital is under no duty to update any of these forward-looking statements after the date of this press release, nor to conform prior statements to actual results or revised expectations, and BrightSpire Capital does not intend to do so.

Investor Relations

BrightSpire Capital, Inc.

Addo Investor Relations

Lasse Glassen

310-829-5400

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Communications Finance Construction & Property REIT Public Relations/Investor Relations

MEDIA:

Logo
Logo

Premier Financial Bancorp, Inc. Reports Second Quarter 2021 Earnings

PR Newswire

HUNTINGTON, W.Va., Aug. 4, 2021 /PRNewswire/ — PREMIER FINANCIAL BANCORP, INC. (PREMIER), (NASDAQ/GMS-PFBI), a $2.1 billion financial holding company with two community bank subsidiaries, announced its financial results for the second quarter of 2021.  Premier realized net income of $5,174,000 (35 cents per diluted share) during the quarter ended June 30, 2021, a 6.0% decrease from the $5,506,000 of net income reported for the second quarter of 2020.  The decrease in net income in the second quarter of 2021 is largely due to an increase in non-interest expenses, primarily professional fees and expenses and writedowns of other real estate owned (“OREO”).  The increase in non-interest expense more than offset positive quarter-over-quarter earnings comparisons in 2021, such as increases in net interest income and non-interest income and a decrease in the provision for loan losses when compared to the second quarter of 2020.  On a diluted per share basis, Premier earned $0.35 during the second quarter of 2021 compared to $0.37 per share earned during the second quarter of 2020.  For the first half of 2021 Premier realized net income of $11,724,000 (79 cents per diluted share), a 7.8% increase from the $10,874,000 (74 cents per diluted share) earned during the first half of 2020.  The annualized returns on average common shareholders’ equity and average assets were approximately 9.22% and 1.21% for the six months ended June 30, 2021, compared to 8.72% and 1.19% for the same period in 2020.

President and CEO Robert W. Walker commented, “Our participation in the Paycheck Protection Program (“PPP”) has been a great success for our company, as we have increased our loan balances outstanding, increased our loan interest income and fostered new customer relationships upon which to build.  We continue to be more and more encouraged and expect future economic conditions to continue to recover as a result of declining trends in the spread of the COVID-19 virus.  As a result, we have lowered our qualitative estimate of credit risk analysis of the loan portfolio for potential COVID-19 related loan losses and reduced our provision for loan loss expense.  We are also pleased with continued increases in our non-interest income as customers return to pre-COVID-19 activity levels and our electronic banking income sets new quarterly highs.  As this is likely to be the last quarterly reporting of financial results for Premier as a stand alone company, I continue to be very proud of our management and staff team members as they have risen to the occasion and successfully guided our great company over the years.  It has truly been my pleasure to be part of the team.  I wish to express our sincerest thanks for all of the great support from our shareholders and look forward to the continued financial success of our combined company.”

Net interest income for the quarter ended June 30, 2021 totaled $16.946 million, up $137,000, or 0.8%, from the $16.809 million of net interest income earned in the second quarter of 2020, as interest expense savings exceeded a decrease in interest income.  Interest income in 2021 decreased by $1,035,000, or 5.6%, in the second quarter when compared to the second quarter of 2020, largely due to a $640,000, or 29.1%, decrease in interest income on investment securities, and a $392,000, or 2.4%, decrease in interest income on loans.  Interest income on interest-bearing bank balances and federal funds sold decreased by $3,000, or 11.5%, in the second quarter of 2021 when compared to the same quarter of 2020, due to lower earning yields on slightly lower average balances.  Similarly, interest income on investment securities in the second quarter of 2021 decreased by $640,000, or 29.1%, when compared to the second quarter of 2020.  While the average balance of investments increased by $142.4 million in the second quarter of 2021 when compared to the same quarter of 2020, the average yield earned decreased from 2.23% during the second quarter of 2020 to 1.17% during the second quarter of 2021.  The decrease in the average yield earned is largely due to accelerated prepayments of mortgage-backed securities which resulted in a corresponding higher rate of purchase premium amortization on these securities, as well as a significantly lower reinvestment yield on the accelerated prepayment funds and investments purchased with funds from the growth in deposit balances and customer repurchase agreements.  Interest income on loans decreased by $392,000, or 2.4%, in the second quarter of 2021 when compared to the second quarter of 2020.  Interest income on loans in the second quarter of 2021 included approximately $50,000 of income recognized from deferred interest and discounts recognized on loans that paid off during the quarter, compared to approximately $468,000 of interest income of this kind recognized during the second quarter of 2020.  Otherwise, interest income on loans increased by $26,000, or 0.2%, in the second quarter of 2021.  The increase in interest income on loans is a combination of a decrease in interest income on real estate mortgage and consumer loans that was more than offset by an increase in interest income on commercial loans.  Interest income on real estate mortgage and consumer loans decreased by $516,000, or 12.0%, in the second quarter of 2021 when compared to the second quarter of 2020, largely due to a lower average yield earned on a lower average balance of these loans outstanding.  Conversely, interest income on commercial loans increased by $542,000, or 4.7%, in the second quarter of 2021 when compared to the second quarter of 2020, largely due to a higher average balance of these loans outstanding earning a similar yield in 2021 compared to the second quarter of 2020.  Premier’s participation in the U.S. Treasury’s and Small Business Administration’s Paycheck Protection Program (“PPP”) accounted for $17.4 million of the $40.6 million increase in average commercial loans outstanding in the second quarter of 2021 compared to the second quarter of 2020.  In addition, interest income on PPP loans and the recognition of fee income when a borrower’s PPP loan is paid off resulted in a $1,194,000 increase in loan interest income in the second quarter of 2021 compared to the second quarter of 2020.

More than offsetting the decrease in interest income in the second quarter of 2021 was a $1,172,000, or 64.1%, decrease in interest expense, driven by a decrease in interest expense on deposits.  Interest expense on deposits decreased by $1,129,000, or 65.8% in the second quarter of 2021, largely due to decreases in the average rate paid on certificates of deposit, savings deposits, and NOW and money market deposits during the second quarter of 2021 compared to the same quarter in 2020.  Further interest expense savings were realized due to decreases in the average balance of higher-costing certificates of deposit during the second quarter of 2021 compared to the same quarter in 2020.  Nevertheless, average interest-bearing deposit balances increased by $58.9 million, or 5.2%, in the second quarter of 2021 compared to the same quarter of 2020, largely due to a $53.8 million, or 19.2%, increase in savings deposits and a $79.0 million, or 16.7%, increase in NOW and money market deposits.  These increases more than offset a $73.9 million, or 19.5%, decrease in certificate of deposit balances.  As certificates mature, depositors are either seeking higher deposit rates from other competitive depository institutions or are transferring their balances to more liquid interest-bearing deposit accounts such as NOW, money market and savings deposits as a means to keep immediate access to their funds during the uncertainty of employment or economic conditions.  The average interest rate paid on interest-bearing deposits decreased by 41 basis points from 0.61% during the second quarter of 2020 to 0.20% during the second quarter of 2021, as Premier eliminated its interest rate specials on certificates of deposit and lowered the interest rate paid on all deposit products in response to decreases in the short-term interest rate policy of the Federal Reserve Board of Governors.  Decreases in short-term rates resulting from actions by the Federal Reserve Board of Governors to reduce the targeted federal funds rate, plus an inflow of funds from direct stimulus payments from the U.S. Treasury to deposit account holders have resulted in a decrease in competition for bank deposit rates.  As a result, the average interest rate paid on highly liquid NOW and money market deposits decreased by 8 basis points and the average rate paid on savings deposits decreased by 9 basis points in the second quarter of 2021 when compared to the second quarter of 2020.  Even with these resulting decreases in the average rate paid on transaction based deposits, the average outstanding balance of transaction-based deposits increased.  Interest expense savings on interest-bearing transaction deposit accounts totaled $143,000 of the $1,129,000 decrease in interest expense on interest-bearing deposits.  The remaining $986,000 decrease in interest expense on deposit accounts came from a decrease in average outstanding certificates of deposits and a 93 basis point decrease in the average rates paid during the second quarter of 2021 when compared to the second quarter of 2020. 

Similarly, interest expense paid on short-term borrowings, primarily customer repurchase agreements, decreased by $3,000, or 20%, in 2021.  The reduction in interest expense was largely due to a 14 basis point decrease in the average rate paid, partially offset by an 86.8% increase in the average balance outstanding during the second quarter of 2021.  Also contributing to the overall 64.1% decrease in interest expense during the second quarter of 2021 was a $23,000, or 100%, decrease in interest expense on FHLB borrowings and a $17,000, or 22.4%, decrease in interest expense on Premier’s subordinated debt.  All FHLB borrowings were repaid in 2020 resulting in no interest expense during the second quarter of 2021.  Premier’s subordinated debt features a variable interest rate indexed to the short-term three-month LIBOR interest rate, which was lower in the second quarter of 2021 compared to the second quarter of 2020 in conjunction with decreases in short-term interest rate policy by the Federal Reserve Board of Governors. 

During the quarter ended June 30, 2021, Premier recorded $428,000 of provision for loan losses compared to $590,000 of provision for loan losses recorded during the same quarter of 2020.  A significant portion of the provision for loan losses recorded during the second quarter of 2020 was primarily to provide for an estimate of additional identified credit risk in the loan portfolio due to uncertainty related to future economic conditions resulting from government actions designed to curb the spread of the COVID-19 virus.  Premier added approximately $1,000,000 to its qualitative credit risk analysis of the loan portfolio related to loans originated to various industries believed to be more susceptible to future credit risk resulting from an economic slowdown such as lodging, restaurants, amusement, personal services and retail stores during the second quarter of 2020.  During the remainder of 2020 and into the first quarter of 2021, Premier refined its estimates on the qualitative credit risk analysis of the loan portfolio related to COVID-19 and added approximately $250,000 of additional provision during the first quarter of 2021 to the estimated $2.5 million of qualitative credit risk analysis related to COVID-19 at year-end 2020.  Due to improvements in the economy during the second quarter of 2021, the elimination of virtually all loan payment deferrals under the CARES Act, and the resumption of regular payments on loans originated to the various industries believed to be more susceptible to future credit risk under COVID-19, Premier reduced its estimate of the qualitative credit risk analysis of the loan portfolio related to COVID-19 by approximately $1,000,000.  More than offsetting this decrease,  the net provision expense in the second quarter of 2021 was related primarily to increases in specific reserves on impaired commercial real estate secured loans that were eventually charged-off by the end of the quarter. 

The $1,000,000 of additional provision expense related to Potential COVID-19 Losses in the second quarter of 2020 was partially offset by reductions in estimated credit risk within the loan portfolio resulting from decreases in loans outstanding, such as owner-occupied commercial real estate and multifamily real estate loans, as well as higher risk loans, such as commercial and industrial loans, construction and land development loans and consumer loans.  Other indications of improving portfolio credit risk that occurred during the second quarter of 2020 include decreases in loans classified as Special Mention and Substandard, improvements in past due ratios and decreases in historical loss ratios.  The level of provision expense is determined under Premier’s internal analyses of evaluating credit risk.  The amount of future provisions for loan losses will depend on any future improvement or further deterioration in the estimated credit risk in the loan portfolio, as well as whether additional payments are received on loans previously identified as having significant credit risk.  Gross charge-offs of loans totaled $1,320,000 in the second quarter of 2021 compared to $109,000 of gross charge-off of loans in the second quarter of 2020.  Recoveries on loans previously charged-off was relatively the same in 2021 at $47,000 compared to $51,000 in the second quarter of 2020.  During the first six months of 2021, net charge-offs increased by $587,000 to $1,331,000, compared to the same six months of 2020.  Also during the first six months of 2021, non-accrual loans increased by $2,968,000 since year-end 2020, while accruing loans over 90 days past due decreased by $1,423,000.

Net overhead costs (non-interest expenses less non-interest income) for the quarter ended June 30, 2021 totaled $9.697 million compared to $9.189 million in the second quarter of 2020.  Net overhead increased by $508,000, or 5.5%, in the second quarter of 2021 when compared to the second quarter of 2020, largely due to a $740,000, or 6.7%, increase in non-interest expense partially offset by a $232,000, or 12.3%, increase in non-interest income.  Total non-interest income increased by $232,000 in the second quarter of 2021 when compared to the second quarter of 2020, largely due to a $164,000, or 17.5%, increase in electronic banking income and a $35,000, or 41.2%, increase in secondary market mortgage income.  Electronic banking income increased, largely due to a $163,000, or 20.9%, increase in income from debit card transaction activity.  Secondary market mortgage income increased, in part, due to the lower long-term interest rate environment, resulting in an increase in housing purchases in Premier’s markets and home loan refinances as customers are taking advantage of lowering their long-term fixed home loan interest rate.  Other increases in non-interest income include a $15,000, or 2.2%, increase in service charges on deposit accounts, largely due to an increase in customer overdraft activity, and an $18,000, or 10.2%, increase in other sources of non-interest income, including check cashing fees, checkbook sales, and income from Premier’s partial ownership of an insurance agency. 

Non-interest expense increased by $740,000, or 6.7% in the second quarter of 2021 compared to the second quarter of 2020, largely due to a $641,000, or 181%, increase in expenses and writedowns on OREO properties and a $217,000, or 88.2%, increase in professional fees.  During the second quarter of 2021, Premier recorded $859,000 of writedowns on OREO property values and another $14,000 of net losses on the completed sale of OREO properties compared to $277,000 of such writedowns of OREO property values and the realization of $28,000 of net gains upon the sale of OREO properties in the second quarter of 2020. Professional fees increased largely due to a $171,000 increase in legal fees and a $25,000 increase in consulting fees related to the pending acquisition of Premier by Peoples Bancorp Inc.  Other increases in non-interest expense include a $52,000, or 72.2%, increase in FDIC insurance costs, largely due to the prior utilization of FDIC based community bank assessment credits to partially offset the second quarter 2020 FDIC insurance premiums, a $30,000, or 1.8%, increase in outside data processing costs and a $13,000, or 0.7%, increase in occupancy and equipment expenses.  These increases more than offset decreases in non-interest expense in the second quarter of 2021 when compared to the second quarter of 2020.  Decreases in non-interest expense include an $80,000, or 31.7%, decrease in taxes not on income, a $74,000, or 73.3%, decrease in loan collection expenses, a $21,000, or 18.4%, decrease in supplies expense, an $18,000, or 7.5%, decrease in the amortization of intangible assets and a $20,000, or 0.4%, decrease in staff costs.  The decrease in taxes not on income is due to a change in the taxation of banks in the Commonwealth of Kentucky, from an equity based franchise tax to a state imposed income tax. 

Total assets as of June 30, 2021 were up $134.1 million, or 6.9%, to $2.080 billion from the $1.946 billion of total assets at year-end 2020.  Liquid assets, such as cash and due from banks, interest bearing bank balances and federal funds sold, decreased by $45.6 million, largely due to investment purchases during the first six months of 2021.  Investment securities increased by $151.6 million, or 36.0%, since year-end 2020, largely due to $289.3 million of new purchases.  These increases more than offset $104.9 million of proceeds from monthly principal payments on Premier’s mortgage backed securities portfolio and securities that matured or were called, $25.5 million of proceeds from the sale of a limited number of mortgage-backed securities and a $5.5 million decrease in the market value of the securities available for sale.  Total loans outstanding increased by $31.6 million, or 2.6%, as Premier generated $14.4 million of new PPP loans, net of forgiveness payments received, during the first six months of 2021 plus another $17.2 million, or 1.4%, increase in traditional loans as new loans generated during the first six months exceeded payoffs and principal payments received.  During the second quarter of 2021, Premier received approximately $26.3 million of PPP loan forgiveness payments resulting in the recognition of approximately $1.8 million of net deferred loan fees into interest income on loans during the quarter.  Since year-end 2020, Premier has received approximately $49.3 million of PPP loan forgiveness payments resulting in the recognition of approximately $2.5 million of net deferred loan fees into interest income on loans during the first six months of 2021.  Other real estate owned (“OREO”) decreased by $1,173,000, or 8.9%, largely due to $859,000 of writedowns on OREO property carrying values  as well as sales of OREO properties exceeding new foreclosures during the first six months of 2021.  Total deposits increased by $93.0 million, or 5.7%, since year-end 2020.  The overall increase in deposits was largely due to a $31.9 million, or 6.5%, increase in non-interest bearing deposits, a $48.6 million, or 13.6%, increase in interest bearing transaction deposits, and a $36.4 million, or 7.9%, increase in savings and money market deposits.  Partially offsetting these increases, certificates of deposit balances decreased by $23.8 million, or 7.3% during the first six months of 2021.  Similarly, customer repurchase agreements increased by $28.4 million, or 84.0%, since year-end 2020.  Premier’s subordinated debentures increased by $20,000 since year-end 2020 due to the accretion of purchase accounting fair value adjustments applied to the $6.186 million face value of the subordinated debentures.  Other liabilities increased by $23.4 million, largely due to $26.0 million of investment security purchases during the last days of June 2021 for which the purchase proceeds were not required to be remitted until July 2021. 

Stockholders’ equity of $249.2 million equaled 12.0% of total assets at June 30, 2021, which compares to stockholders’ equity of $259.9 million, or 13.4% of total assets, at December 31, 2020.  The decrease in stockholders’ equity was largely due to the normal first and second quarter cash dividends declared totaling $0.30 per share and also a $1.00 per share special cash dividend declared in January of 2021 and paid in February of 2021.  The dividends combined to reduce stockholders’ equity by $19.1 million.  Furthermore, a decrease in the market value of the investment portfolio available for sale reduced stockholders’ equity by $4.3 million, net of tax.  These decreases in stockholders’ equity were partially offset by the $11.7 million of net income earned during the first six months of 2021 and approximately $1.0 million of contributed capital from the exercise of employee stock options during the first six months of 2021.

Certain Statements contained in this news release, including without limitation statements including the word “believes,” “anticipates,” “intends,” “expects” or words of similar import, constitute “forward-looking statements” within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from any future results, performance or achievements of Premier expressed or implied by such forward-looking statements. Furthermore, uncertainty related to future economic conditions resulting from government actions designed to curb the spread of the COVID-19 virus may affect Premier’s operations more or less than currently estimated.  Such factors include, among others, general economic and business conditions, changes in business strategy or development plans and other factors referenced in this press release. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Premier disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments. 

Following is a summary of the financial highlights for Premier as of and for the periods ended June 30, 2021




PREMIER FINANCIAL BANCORP, INC.

Financial Highlights

Dollars in Thousands (except per share data)

For the

Quarter Ended

For the

Six Months Ended

June 30

June 30

June 30

June 30

2021

2020

2021

2020

Interest Income

   Loans, including fees

16,024

16,416

31,472

32,170

   Investments and other

1,579

2,222

3,118

5,112

      Total interest income

17,603

18,638

34,590

37,282

Interest Expense

   Deposits

586

1,715

1,351

3,880

   Borrowings and other

71

114

143

251

      Total interest expense

657

1,829

1,494

4,131

   Net interest income

16,946

16,809

33,096

33,151

Provision for loan losses

428

590

1,076

1,590

   Net interest income after provision

16,518

16,219

32,020

31,561

Non-interest Income

   Service charges on deposit accounts

707

692

1,440

1,798

   Electronic banking income

1,101

937

2,108

1,755

   Gain on the sale of securities

1,096

   Other non-interest income

314

261

622

586

      Total non-interest income

2,122

1,890

5,266

4,139

Non-Interest Expense

   Salaries and employee benefits

5,247

5,267

9,862

10,675

   Net occupancy and equipment

1,811

1,798

3,600

3,523

   Outside data processing

1,732

1,702

3,449

3,233

   OREO expenses and writedowns, net

995

354

1,159

422

   Amortization of intangibles

223

241

445

483

   Other non-interest expenses

1,811

1,717

3,494

3,480

      Total non-interest expense

11,819

11,079

22,009

21,816

   Income Before Taxes

6,821

7,030

15,277

13,884

Income Taxes

1,647

1,524

3,553

3,010


   NET INCOME


5,174


5,506


11,724


10,874


   EARNINGS PER SHARE


0.35


0.38


0.80


0.74


   DILUTED EARNINGS PER SHARE


0.35


0.37


0.79


0.74

   DIVIDENDS PER SHARE

0.15

0.15

1.30

0.30

Charge-offs

1,320

109

1,429

935

Recoveries

47

51

98

191

   Net charge-offs

1,273

58

1,331

744

 


PREMIER FINANCIAL BANCORP, INC.

Financial Highlights (continued)

Dollars in Thousands (except per share data)

Balances as of

June 30

December 31

2021

2020


ASSETS

Cash and due from banks

24,265

24,961

Interest-bearing bank balances

124,523

174,209

Federal funds sold

16,047

11,306

Securities available for sale

572,785

421,190

Loans (net)

1,232,701

1,200,862

Other real estate owned

12,042

13,215

Other assets

45,917

48,015

Goodwill and other intangible assets

51,619

52,064


   TOTAL ASSETS


2,079,899


1,945,822


LIABILITIES & EQUITY

Deposits

1,726,782

1,633,740

Fed funds/repurchase agreements

62,256

33,827

Subordinated debentures

5,495

5,475

Other liabilities

36,181

12,873


   TOTAL LIABILITIES


1,830,714


1,685,915

Common Stockholders’ Equity

249,185

259,907


   TOTAL LIABILITIES &


      STOCKHOLDERS’ EQUITY


2,079,899


1,945,822


TOTAL BOOK VALUE PER COMMON SHARE


16.84


17.71


Tangible Book Value per Common Share


13.35


14.16

Non-Accrual Loans

11,964

8,996

Loans 90 Days Past Due and Still Accruing

909

2,332

 

Cision View original content:https://www.prnewswire.com/news-releases/premier-financial-bancorp-inc-reports-second-quarter-2021-earnings-301347866.html

SOURCE Premier Financial Bancorp, Inc.